Saturday

27th May 2017

Media lift lid on secret reports on drug side-effects

  • The industry says documents of this type are easily misunderstood and misinterpreted. (Photo: www.freeimages.co.uk)

Adverse reactions to medication is the fifth most common cause of death in hospitals according to the European Commission, but EU agencies and national governments have until now kept secret pharmaceutical companies' reports on side-effects.

The notes - known in the business as Periodic Safety Update Reports (PSURs) - are submitted regularly to national authorities and the European Medicines Agency in London.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

The PSURs for example detail how doctors in various countries suspect that teenagers grow suicidal when taking a certain medication against pimples, or that a diet product could lead to a stroke and what industry has to say about the medical fears.

A team of Dutch, Danish and Belgian journalists has now used freedom of information legislation in the Netherlands and Denmark to get partial access to the documents, where patient gender, age and country of origin are blacked out to protect privacy and business interests. A legal decision is pending in Belgium.

The move by Dutch daily newspaper Trouw, Belgian magazine Knack in cooperation with Danish magazine Samvirke to put the documents on the internet comes as the European Commission on Tuesday (22 October) decided to delay the publication of a new package of regulation for drugs producers.

The commission package is not expected to mandate publication of PSURs but is likely to allow pharmaceutical companies to contact patients directly - a practice that is currently illegal and was condemned by the European Parliament in 2002.

"In my view, there can be no doubt that PSURs should be made public. After all this is about the side-effects on medicines that we take," Margrethe Nielsen, a researcher at the Cochrane Institute's Copenhagen branch and a specialist on pharmaceuticals told EUobserver.

She added that the notes, which form the basis of government understanding of the sector, are not based on clinically controlled tests method. "This is maybe the most important: this does not build on sound science," she said. "I would not be able to use them for my work."

"In these reports [released in the Netherlands and Denmark] much too much has been blackened. The quality is unequal. It is of big importance that these safety reports can be accessible for everybody so that scientists can debate about their quality," Canadian expert Barbara Mintzes told Knack.

Reacting in a test case on PSUR publication in Denmark in 2007, lawyers for drug firm Roche threatened to sue the Danish state if disclosure harmed the company's commercial interests.

"A competitor can use the reports as a basis for guidance to patients and guidance to doctors. Competitors can with the help of PSUR reports obtain a basis to take care of guiding functions, that can weaken Roches position on the market and thus bring significant negative economic effects for Roche worldwide," the company's legal advisors wrote in letters to Danish authorities.

"Experience shows, that documents of this type are easily misunderstood and misinterpreted, for example by journalists," the letters add. "Misunderstandings of this type can cause severe disturbance of the market and thus loss for Roche."

The view is shared by the Brussels-based trade lobby, the European Federation of Pharmaceutical Industries and Associations (EFPIA), today.

"The trouble is, they have to be understandable. You need to be an expert, to understand them. I would push that back to the regulator to take proper action. When you pull information, it has to be in a form, that you and I can understand," EFPIA director Brian Ager said.

"The industry claims that the people wouldn't understand them. In reality making the side effects public would influence the stock exchange in a negative way," French medical journal Prescire's editor Bruno Toussaint said.

Nato head defends 'blunt' US leader

Nato chief Stoltenberg defended Trump’s behaviour at Thursday’s summit. The prime minister of Montenegro also apologised for him.

Trump lukewarm on Nato joint defence

Trump voiced half-hearted support for Nato and reprimanded allies over what he called unpaid debts on his maiden trip to Europe.

Nato to join Trump's anti-IS coalition

Nato will join a US-led coalition against Islamic State and will continue to deter "Russian aggression" its secretary general has said.

Trump expected to make Nato pledge

Nato mutual defence and the fight against Islamic State to take centre stage as US leader meets Nato and EU allies in Brussels.

Trump lukewarm on Nato joint defence

Trump voiced half-hearted support for Nato and reprimanded allies over what he called unpaid debts on his maiden trip to Europe.

News in Brief

  1. Malloch will not be US ambassador to the EU
  2. 'Significant' drop in EU migration to UK
  3. Bomb injures former Greek PM
  4. British PM to speak out on US terrorism leaks
  5. Tusk calls for 'values, not just interests' after Trump meeting
  6. Pressure grows on climate impact of EU timber harvesting
  7. US goes after Fiat Chrysler over emissions cheat
  8. Munich police break up Europe-wide burglar clan

Stakeholders' Highlights

  1. UNICEFChild Alert on Myanmar: Fruits of Rapid Development yet to Reach Remote Regions
  2. Nordic Council of MinistersBecome an Explorer - 'Traces of Nordic' Seeking Storytellers Around the World
  3. Malta EU 2017Closer Cooperation and Reinforced Solidarity to Ensure Security of Gas Supply
  4. European Healthy Lifestyle AllianceHigh-Intensity Interval Training Is Therapeutic Option for Type 2 Diabetes
  5. Dialogue Platform"The West Must Help Turkey Return to a Democratic Path" a Call by Fethullah Gulen
  6. ILGA-EuropeRainbow Europe 2017 Is Live - Which Countries Are Leading on LGBTI Equality?
  7. Centre Maurits CoppietersWhen You Invest in a Refugee Woman You Help the Whole Community
  8. Eurogroup for AnimalsECJ Ruling: Member States Given No Say on Wildlife Protection In Trade
  9. European Heart NetworkCall for Urgent Adoption of EU-Wide Nutrient Profiles for Nutrition & Health Claims
  10. Counter BalanceInvestment Plan for Europe More Climate Friendly but European Parliament Shows Little Ambition
  11. Mission of China to the EUPresident Xi: China's Belt and Road Initiative Benefits People Around the World
  12. Malta EU 2017EU Strengthens Control of the Acquisition and Possession of Firearms